Cambridge biotech startup PACT has raised €10.7 million in a seed funding round to scale its pioneering biomaterials technology inspired by nature. The investment was led by Hoxton Ventures, with additional backing from ReGen Ventures, Celsius Industries, and Polytechnique Ventures.
The funding will enable PACT to expand production of its innovative collagen-based materials, invest in further research, and bring new biomaterial solutions to industries like fashion, luxury, and beyond. Central to this growth is a new 13,820-square-foot headquarters in Cambridge, featuring a laboratory and pilot production facility that will help transition PACT from development to large-scale commercialisation.
PACT’s CEO, Yudí Ding, emphasised the company’s vision: “Our goal is to craft beautiful, adaptable materials derived from the natural world. By partnering with luxury Maisons, we are entering a new era where sustainability and elegance are intertwined.”
Founded in 2020 by Ding and COO Niels Ramay, PACT’s technology is based on research from the University of Cambridge, with a focus on developing biomaterials from natural proteins, herbal extracts, and minerals. The company’s flagship material, Oval, is the world’s first scalable, climate-responsible biomaterial made from natural collagen, which has already garnered interest from leading luxury fashion houses.
With plans to expand into footwear, interiors, and automotive industries, PACT is set to revolutionise the biomaterials landscape. Charles Seely of Hoxton Ventures praised the company’s innovation, stating: “PACT combines the aesthetics of heritage materials with high-performance, scalable production that meets the demands of luxury and beyond.”
PACT’s scalable collagen technology is poised to make a significant impact across industries, setting the stage for a new era of sustainable, nature-inspired materials.
